Ask My Investor AI
Public company · NasdaqPublished company research
GEHC

Legal identity, Nasdaq ticker, USD reporting and SEC CIK are confirmed by the FY2025 Form 10-K and the issuer's Q1 2026 release.

GE HealthCare Technologies Inc.

GE HealthCare has direct nuclear-medicine capability through its Pharmaceutical Diagnostics segment, PET/SPECT imaging systems and an expanding molecular-imaging portfolio. Q1 2026 Pharmaceutical Diagnostics revenue was $770M and segment EBIT was $197M, but those figures include contrast media and other imaging agents. Flyrcado is a directly supported growth product with an issuer target of more than $500M of annual revenue by 2028. Current isotope-specific revenue, margins and licensed valuation are unavailable, so the subject remains NOT_READY pending human review.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
GEHC
Exchange
Nasdaq
HQ
United States
Currency
USD
SEC CIK
0001932393
Investment case

How this company captures the theme economics

Competitive position

The company combines a global installed base of imaging equipment with Pharmaceutical Diagnostics agents and software. Flyrcado's 109-minute half-life permits offsite production and unit-dose distribution, while the broader portfolio spans cardiology, neurology and oncology. This supports an integrated workflow position, but official disclosures do not isolate nuclear-medicine economics from the broader segment.

Scarce assets

FDA-approved molecular-imaging agents, a contract-manufacturing and distribution network for time-sensitive PET doses, a global PET/SPECT installed base, quantitative imaging software, regulatory dossiers and clinical evidence.

Products, segments, and customers

Reportable segments include Advanced Imaging Solutions, Patient Care Solutions and Pharmaceutical Diagnostics. Medical-isotope exposure sits primarily in Pharmaceutical Diagnostics through Flyrcado, Vizamyl, Cerianna and DaTscan, and in imaging systems and software used for PET, SPECT and theranostics workflows.

Theme capture

GE HealthCare captures adoption economics through radiopharmaceutical sales, PET/SPECT equipment, cyclotron and tracer-production tools, and workflow software. Q1 2026 PDx segment scale is disclosed, but medical-isotope revenue is not separately reported, so relationship magnitude is not assessed.

Conditions

What must be true

  1. Flyrcado adoption and distribution must scale toward the issuer's more-than-$500M annual target without reimbursement or manufacturing constraints.
  2. Nuclear-medicine products and theranostics workflows must become material within Pharmaceutical Diagnostics and the imaging franchise rather than remaining a small subset of broader segment revenue.

Identifiable catalysts

  • Broader 2026 Flyrcado rollout across hospital, outpatient and mobile cardiac PET settings.
  • Expansion of PET, SPECT and adaptive-theranostics workflows as radioligand therapy adoption grows.
  • Quarterly disclosure that isolates Flyrcado or nuclear-medicine revenue and margins.
Theme materiality

2 mapped themes

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Radiopharmaceutical diagnostics, PET/SPECT imaging equipment and software-enabled theranostics workflows.

Medical isotopes and radiopharmaceutical logistics

Direct operating capability but unresolved theme-specific magnitude. Q1 2026 Pharmaceutical Diagnostics revenue was $770M, up 21.7%, with $197M of segment EBIT; the issuer identifies Flyrcado as a growth contributor and targets more than $500M of annual Flyrcado revenue by 2028. PDx also includes contrast media and other agents, so these segment figures are only upper bounds for medical-isotope exposure.

Evidence
The Q1 2026 results, official earnings slides and June 2026 nuclear-medicine release directly support segment scale, the Flyrcado target and the PET/SPECT/theranostics capability. No official source reviewed separates current isotope-linked revenue or margin.
Materiality
not assessed — Pharmaceutical Diagnostics is material and separately reported, but medical-isotope products are not separated from contrast media and other imaging agents; the Flyrcado target is prospective rather than current realized revenue.
Women's imaging through mammography, breast ultrasound and related AI workflows.

Women's health formalization

Direct product exposure inside a diversified imaging franchise, with no separately disclosed women's-health revenue in the sources reviewed.

Evidence
This bounded pass did not re-review the women's-health mapping; it remains fail-closed on standalone economics.
Materiality
not assessed — Women's-health revenue and profit are not separately disclosed.
Financial evidence

Official public disclosures

Reference period: FY2025 and Q1 2026.

  • Total revenue$5.1B; +7.4% year over year
    Q1 2026[2]
  • Net income attributable to GE HealthCare$389M
    Q1 2026[2]
  • Pharmaceutical Diagnostics revenue$770M; +21.7% year over year
    Q1 2026[2]
  • Pharmaceutical Diagnostics segment EBIT$197M; 25.6% margin
    Q1 2026[2]
  • Flyrcado annual revenue target>$500M by 2028; prospective issuer target
    Q1 2026 presentation[3]
  • Operating income$2.76B
    FY2025[1]
  • Net income attributable to common stockholders$2.08B
    FY2025[1]
  • Diluted EPS$4.55
    FY2025[1]

Limitation: PDx segment figures are not medical-isotope figures. Current Flyrcado revenue, isotope-linked margins and licensed market valuation are unavailable; the more-than-$500M Flyrcado figure is a prospective issuer target, not realized revenue.

Risks

Material risks and break conditions

Material risks

  • Flyrcado adoption may lag the issuer target because of reimbursement, site enablement, manufacturing or competing tracers.
  • PDx profitability is exposed to supplier interruptions, input costs and product mix; Q1 2026 margin declined year over year.
  • Nuclear-medicine exposure may remain too small within the diversified enterprise to drive equity outcomes.

Thesis-break conditions

  • Flyrcado rollout stalls and the issuer withdraws or materially reduces the more-than-$500M annual target.
  • PDx growth ceases to outpace the group while nuclear-medicine products remain financially undisclosed.
  • PET/SPECT and theranostics workflow demand fails to translate into equipment, agent or software growth.
Investability conclusion

Where the evidence lands

NOT_READY. Identity, capability, current segment results and the Flyrcado target are supported by official sources, but current medical-isotope revenue and margins are not isolated. Licensed valuation and human reviewer acceptance are absent.

Next diligence

  1. Obtain current Flyrcado revenue, dose volume, manufacturing coverage and margin evidence.
  2. Separate nuclear-medicine economics from broader Pharmaceutical Diagnostics and imaging results.
  3. Add licensed current valuation before any price or entry judgment.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. GE HealthCare Technologies Inc. FY2025 Form 10-KU.S. Securities and Exchange Commission · primary · published 2026-02-04 · accessed 2026-07-29
  2. GE HealthCare reports first quarter 2026 financial resultsGE HealthCare Technologies Inc. · primary · published 2026-04-29 · accessed 2026-07-29
  3. GE HealthCare Q1 2026 earnings presentationGE HealthCare Technologies Inc. · primary · published 2026-04-29 · accessed 2026-07-29
  4. GE HealthCare focuses on expanding access to nuclear medicine through AI, radiopharmaceutical and imaging innovationsGE HealthCare Technologies Inc. · primary · published 2026-06-01 · accessed 2026-07-29